药物相互作用与药物基因组学间的转化知识发现
通过整合DDI与DGI证据,发现了119个与CYP3A相关和18个与CYP2D6相关的新药物基因组学假设。
要点
- 信息检索模型可从海量文献中自动提取DDI与DGI证据。
- 整合DDI与DGI证据可发现新的药物基因组学假设。
- 部分DGI证据有助于理解DDI机制。
核心结论
- 整合DDI与DGI证据可发现新的药物基因组学假设,并辅助理解DDI机制。
研究设计与样本
- 开发信息提取模型从检索到的摘要中提取DDI对和DGI对。
主要发现
- 重叠分析在三种类型证据间识别出986个独特DDI对。
- 从已知临床PK/PD DDI、临床PD DDI和DGI证据中分别识别出2157、13012个DDI对和3173个DGI对。
- 整合DDI与DGI证据发现119个与CYP3A相关和18个与CYP2D6相关的新药物基因组学假设。
临床怎么用
- 临床药学智能体可利用此类证据整合思路,关联DDI与药物基因组学信息辅助个体化用药评估。
局限性
- 信息检索与提取模型基于PubMed摘要,可能受文献报告偏倚和摘要信息不完整的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Clinical translation of drug-drug interaction (DDI) studies is limited, and knowledge gaps across different types of DDI evidence make it difficult to consolidate and link them to clinical consequences. Consequently, we developed information retrieval (IR) models to retrieve DDI and drug-gene interaction (DGI) evidence from 25 million PubMed abstracts and distinguish DDI evidence into in vitro pharmacokinetic (PK), clinical PK, and clinical pharmacodynamic (PD) studies for US Food and Drug Administration (FDA) approved and withdrawn drugs. Additionally, information extraction models were developed to extract DDI-pairs and DGI-pairs from the IR-retrieved abstracts. An overlapping analysis identified 986 unique DDI-pairs between all 3 types of evidence. Another 2,157 and 13,012 DDI-pairs and 3,173 DGI-pairs were identified from known clinical PK/PD DDI, clinical PD DDI, and DGI evidence, respectively. By integrating DDI and DGI evidence, we discovered 119 and 18 new pharmacogenetic hypotheses associated with CYP3A and CYP2D6, respectively. Some of these DGI evidence can also aid us in understanding DDI mechanisms.
引用
- Wu HY, Shendre A, Zhang S, et al. Translational Knowledge Discovery Between Drug Interactions and Pharmacogenetics. Clin Pharmacol Ther. 2020. PMID: 31863452. doi:10.1002/cpt.1745
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。